Related Experiment Video
Updated: May 11, 2026

06:00
Portable Paper-Based Immunoassay Combined with Smartphone Application for Colorimetric and Quantitative Detection of Dengue NS1 Antigen
Published on: January 26, 2024
A paper-based fluorescent biosensing platform for miRNA detection with dual high-throughput and smartphone readout
Marianna Rossetti1, Ruslán Alvarez-Diduk1, Liming Hu1
1Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, Bellaterra, Barcelona, 08193, Spain.
Biosensors & Bioelectronics
|May 9, 2026
Summary
We developed a paper-based biosensor for detecting microRNAs (miRNAs) using gold nanoparticles and molecular beacons. This platform offers rapid, quantitative detection suitable for point-of-care diagnostics.
Area of Science:
- Biomedical Engineering
- Molecular Diagnostics
- Nanotechnology
Background:
- MicroRNA (miRNA) detection is crucial for liquid biopsy diagnostics.
- Current methods (qRT-PCR, microarrays) are complex and not point-of-care friendly.
- There is a need for rapid, accessible miRNA detection platforms.
Purpose of the Study:
- To develop a flexible, dry-reagent paper-based biosensing platform for quantitative miRNA detection.
- To enable rapid and portable miRNA analysis.
- To establish a foundation for point-of-care nucleic acid testing.
Main Methods:
- Utilized fluorescent molecular beacon (MB)-functionalised gold nanoparticles (AuNPs) embedded in nitrocellulose membranes.
- Developed a paper-based assay for target-induced miRNA hybridization and fluorescence signal generation.
- Enabled quantification using microplate readers or a portable smartphone-based optical reader.
Main Results:
- Achieved robust miRNA detection in the low-nanomolar range directly on paper.
- Demonstrated improved apparent affinity compared to solution-based measurements.
- The platform is compatible with amplification strategies for enhanced sensitivity.
Conclusions:
- The developed platform is user-friendly, adaptable, and suitable for decentralized testing.
- It shows potential for point-of-care nucleic acid testing in clinical and resource-limited settings.
- Further sensitivity improvements are needed for direct clinical liquid biopsy analysis without amplification.

